<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Silent and incidentally detected adrenocortical <z:hpo ids='HP_0002664'>neoplasms</z:hpo> are the most frequent abnormality of the adrenal cortex </plain></SENT>
<SENT sid="1" pm="."><plain>The prevalence of these lesions in the general population is around 1%, increases with age and reaches 6% in the seventh decade of life </plain></SENT>
<SENT sid="2" pm="."><plain>Primary <z:hpo ids='HP_0006744'>adrenocortical carcinoma</z:hpo>, on the other hand, a highly <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e>, is rare with an incidence of 1.7 cases per million per year </plain></SENT>
<SENT sid="3" pm="."><plain>Recent progress has been achieved in the understanding of adrenocortical <z:mp ids='MP_0002006'>tumorigenesis</z:mp> by mapping and identification of genes responsible for hereditary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> syndromes like the <z:e sem="disease" ids="C0085390" disease_type="Neoplastic Process" abbrv="LFS">Li-Fraumeni syndrome</z:e>, <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e>, <z:e sem="disease" ids="C0406810" disease_type="Disease or Syndrome" abbrv="NAME">Carney complex</z:e> and the Multiple <z:hpo ids='HP_0100568'>Endocrine Neoplasia</z:hpo> Type I </plain></SENT>
<SENT sid="4" pm="."><plain>Investigation of the clonal composition of <z:e sem="disease" ids="C0001624" disease_type="Neoplastic Process" abbrv="">adrenal tumors</z:e> demonstrates that <z:hpo ids='HP_0006744'>adrenal carcinomas</z:hpo> are generally monoclonal, whereas <z:mp ids='MP_0009044'>adrenal adenoma</z:mp> may be polyclonal in approximately 25% of cases </plain></SENT>
<SENT sid="5" pm="."><plain>These <z:mpath ids='MPATH_270'>adenomas</z:mpath> may have a multicellular origin under the putative action of extra-adrenal and local growth factors </plain></SENT>
<SENT sid="6" pm="."><plain>Oncogenes and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes involved in <z:hpo ids='HP_0006744'>adrenal carcinomas</z:hpo> include mutations in the p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene and rearrangements of the chromosomal locus 11 p15.5 associated with IGF II hyperexpression </plain></SENT>
<SENT sid="7" pm="."><plain>Constitutive activation of the ACTH receptor-G protein-cAMP signal cascade does not play a role in <z:e sem="disease" ids="C0001624" disease_type="Neoplastic Process" abbrv="">adrenal tumor</z:e> formation </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, deletions of the ACTH receptor gene have been recently found in undifferentiated <z:mpath ids='MPATH_270'>adenomas</z:mpath> and in aggressive <z:hpo ids='HP_0006744'>adrenocortical carcinomas</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>This indicates that the signaling pathways responsible for <z:e sem="disease" ids="C0001618" disease_type="Neoplastic Process" abbrv="">adrenocortical tumor</z:e> formation are different from that of other <z:chebi fb="32" ids="24621">endocrine</z:chebi> <z:hpo ids='HP_0002664'>neoplasms</z:hpo> like pituitary and <z:hpo ids='HP_0000854'>thyroid adenomas</z:hpo> </plain></SENT>
</text></document>